EUCTR2006-003976-36-BE进行中（未招募）1 期
An academic monocenter study assessing the safety and efficacy of Lucentis (ranizumab 0.3 mg) administered in conjunction with photodynamic therapy with Visudyne in patients with occult or predominantly classic subfoveal choroidal neovascularization secondary to age-related macular degeneration. - COMBO
Professor Anita Leys - Dienst Oftalmologie UZ St. Rafaël0 个研究点开始时间: 2006年8月9日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patients 50 years of age or greater and woman post menopausal.
- •2. Patients with subfoveal choroidal neovascularisation lesions secondary to AMD, either predominantly classic with VA > 0.1 (Snellen) or occult with no classic component and with VA < 0.4 and > 0.1
- •3. CNV lesion in the study eye is =5400 microns in greatest linear dimension.
- •4. Willing to return for scheduled visits for a 4 month period.
- •5. Only one eye will be assessed in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients who have a BCVA of < 0.1 in both eyes.
- •2. Prior treatment in the study eye with verteporfin, external-beam radiation therapy, subfo-veal focal laser photocoagulation, vitrectomy, submacular surgery, or transpupillary ther-motherapy.
- •3. Previous or current intravitreal drug delivery (e.g., intravitreal corticosteroid injection or device implantation) in the study eye.
- •4. Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within one month preceding Day 1.
- •5. Concomitant use of chronic NSAIDs or steroids (by any route) for the duration of study participation (chronic use is defined as multiple doses taken daily for three or more con-secu¬tive days at any time during the study). Note that ASA (aspirin) taken as low dose” up to 100 mg qd for prophylaxis of MI and/or stroke is permitted during study.
- •6. Current use or of likely need for systemic medications known to be toxic to the lens, ret-ina or optic nerve, including Deferoxamine, Chloroquine/ hydroxychloroquine (Plaquenil), Tamoxifen, Phenothiazines and Ethambutol is excluded.
- •7. History of glaucoma filtration surgery, corneal transplant surgery or extracapsular ex¬traction of cataract with phacoemulsification within six months preceding Day One, or a his¬tory of post-operative complications within the last 12 months preceding Day One in the study eye (, uveitis, cyclitis etc.) .
- •8. History of uncontrolled glaucoma in the study eye (defined as intraocular pressure = 25 mmHg despite treatment with anti-glaucoma mediation).
- •9. History of submacular surgery or other surgical intervention for AMD in the study eye within two months preceding Day 1.
- •10. Aphakia or absence of the posterior capsule in the study eye.
- •11. Previous violation of the posterior capsule in the study eye is also excluded unless it oc-curred as a result of YAG posterior capsulotomy in association with prior, posterior cham-ber intraocular lens implantation.
- •12. Spherical equivalent of the refractive error in the study eye demonstrating more than –8 diopters of myopia.
- •13. Presence of a retinal pigment epithelial tear involving the macula in the study eye
- •14. Angioid streaks or precursors of CNV in either eye due to other causes, such as ocular histoplasmosis, trauma, or pathologic myopia.
- •15. Active intraocular inflammation (grade trace or above) in the study eye.
- •16. Any active infection involving eyeball adnexa.
- •17. Vitreous hemorrhage or history of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the study eye.
研究者
相似试验
进行中（未招募）
1 期
Immune Tolerance Induction with Methotrexate in Hurler SyndromeEUCTR2015-003031-35-GBCentral Manchester University Hospitals NHS Foundation Trust4
尚未招募
不适用
A single centre prospective study on the safety and efficacy of per oral endoscopic myotomy (POEM) in the endoscopic management of achalasia and other oesophageal motility disorderAchalasiaEsophageal Motility DisorderOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonSurgery - Surgical techniquesACTRN12619001011178Royal Adelaide Hospital50
已完成
不适用
Single-Arm, Multicenter Study to Evaluate Safety and Efficacy of Low Frequency Spinal Cord Stimulator in Subjects with Low Back and/or Leg Paiower back painLeg PainLower back painNeurological - Other neurological disordersMusculoskeletal - Other muscular and skeletal disordersACTRN12619001252101Presidio Medical AU, Pty Ltd20
招募中
不适用
Single-Arm, Multicenter, Study to Evaluate Safety and Efficacy of an Ultra-Low Frequency Spinal Cord Stimulator in Subjects with Painful Diabetic NeuropathyPainful Diabetic NeuropathyMetabolic and Endocrine - DiabetesACTRN12621000741886Presidio Medical AU Pty Ltd10
已完成
不适用
Single center, Exploratory Safety Evaluation Study of Transcatheter Closure of Prosthetic Paravalvular RegurgitatioProsthetic paravalvular regurgitation after heart valve replacementJPRN-UMIN000021427ational Cerebral and Cardiovascular Center4